keyword
https://read.qxmd.com/read/38621702/vessel-wall-imaging-in-the-diagnosis-of-antiphospholipid-syndrome-presenting-as-moyamoya-syndrome-a-case-report
#1
JOURNAL ARTICLE
David L Yang, Rachel Thomas, Alice F Ford, Brett L Cucchiara, Donna K George, Jae W Song
Objectives: We describe a case of anti-phospholipid syndrome (APLS) vasculopathy presenting with Moyamoya syndrome (MMS) and show the associated intracranial vessel wall MRI (VWI) findings. Methods: A 37-year-old-woman presented with acute onset dizziness and left-sided weakness. Neurologic exam revealed a left facial droop and left hemiparesis. She underwent a comprehensive laboratory work-up for stroke. Neuroimaging included a CT head, CT angiogram, VWI, and digital subtraction angiography. Results: Work-up revealed a triple-positive APLS antibody profile...
April 15, 2024: Neuroradiology Journal
https://read.qxmd.com/read/38459582/low-cd4%C3%A2-%C3%A2-t-cell-count-is-related-to-specific-anti-nuclear-antibodies-ifn%C3%AE-protein-positivity-and-disease-activity-in-systemic-lupus-erythematosus-pregnancy
#2
JOURNAL ARTICLE
Agnes Torell, Marit Stockfelt, Kaj Blennow, Henrik Zetterberg, Tansim Akhter, Dag Leonard, Lars Rönnblom, Sofia Pihl, Muna Saleh, Christopher Sjöwall, Helena Strevens, Andreas Jönsen, Anders A Bengtsson, Estelle Trysberg, Maria Majczuk Sennström, Agneta Zickert, Elisabet Svenungsson, Iva Gunnarsson, Johan Bylund, Bo Jacobsson, Anna Rudin, Anna-Carin Lundell
BACKGROUND: Lymphopenia, autoantibodies and activation of the type I interferon (IFN) system are common features in systemic lupus erythematosus (SLE). We speculate whether lymphocyte subset counts are affected by pregnancy and if they relate to autoantibody profiles and/or IFNα protein in SLE pregnancy. METHODS: Repeated blood samples were collected during pregnancy from 80 women with SLE and 51 healthy controls (HC). Late postpartum samples were obtained from 19 of the women with SLE...
March 9, 2024: Arthritis Research & Therapy
https://read.qxmd.com/read/38432460/inflammatory-and-vaso-occlusive-ulcers-part-ii-management
#3
REVIEW
Alex Hines, Shannon Kody, Hadir Shakshouk, Nicole Fett, Afsaneh Alavi, Alex Ortega-Loayza
In the second part of this CME, we present an approach for the management of inflammatory and vaso-occlusive ulcers and highlight the need for further research in this field. The three overarching principles for management are etiology-specific treatment, ulcer care, and consideration of patient comorbidities and risk factors for poor healing. Both etiology-specific treatment and management of patient comorbidities and risk factors often require collaboration with providers from other specialties. Ulcer care is governed by TIME, or tissue debridement, infection control, management of moisture imbalance and epithelial edge advancement...
March 1, 2024: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/38432459/inflammatory-and-vaso-occlusive-ulcers-part-i-clinical-presentation-and-diagnosis
#4
REVIEW
Hadir Shakshouk, Alex Hines, Shannon Kody, Nicole Fett, Afsaneh Alavi, Alex G Ortega-Loayza
In this CME, we review two specific categories of ulcers: inflammatory (where inflammation is the primary pathologic process leading to ulceration) and vaso-occlusive (where occlusion is the primary process). Inflammatory ulcers include pyoderma gangrenosum and vasculitides, whereas livedoid vasculopathy, calciphylaxis and Martorell ulcers are vaso-occlusive ulcers. Determining the causes of ulcers in these conditions may require laboratory evaluation, biopsy and imaging.
March 1, 2024: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/38386917/altered-cd226-tigit-expressions-were-associated-with-activated-nk-phenotypes-in-primary-anti-phospholipid-syndrome-and-affected-by-il-4-jak-pathway
#5
JOURNAL ARTICLE
Yan Long, Ke-Jia Lu, Chang-Sheng Xia, Jing-Hong Feng, Wen-Yi Li, Yin-Ting Ma, Yuan-Yuan Sun, Chun-Hong Fan, Chun Li
Natural killer (NK) cells were reported to be involved in the pathogenesis of primary antiphospholipid syndrome (pAPS). Immunosuppressive receptor TIGIT and activating receptor CD226 are specifically expressed on NK cells with competitive functions. This study aims to investigate the expression diversities of CD226/TIGIT on NK subsets and their associations with NK subsets activation phenotypes and potential clinical significance, furthermore, to explore potential cause for CD226/TIGIT expression diversities in pAPS...
February 22, 2024: Clinical and Experimental Immunology
https://read.qxmd.com/read/38322819/adjuvants-in-covid-19-vaccines-innocent-bystanders-or-culpable-abettors-for-stirring-up-covid-heart-syndrome
#6
REVIEW
Sri Harsha Kanuri, Prapthi Jayesh Sirrkay
COVID-19 infection is a multi-system clinical disorder that was associated with increased morbidity and mortality. Even though antiviral therapies such as Remdesvir offered modest efficacy in reducing the mortality and morbidity, they were not efficacious in reducing the risk of future infections. So, FDA approved COVID-19 vaccines which are widely administered in the general population worldwide. These COVID-19 vaccines offered a safety net against future infections and re-infections. Most of these vaccines contain inactivated virus or spike protein mRNA that are primarily responsible for inducing innate and adaptive immunity...
2024: Therapeutic Advances in Vaccines and Immunotherapy
https://read.qxmd.com/read/38322059/recurrent-syncope-unveiling-pulmonary-hypertension-secondary-to-pulmonary-artery-thrombi-in-a-pediatric-patient
#7
Dina AlkhateebAltamimi, Karim Khalidi, Rima Khasawneh, Abdulhadi Alzaben, Khaled Salaymeh
We present a case of a nine-year-old female patient who presented with recurrent syncope and was ultimately diagnosed with pulmonary hypertension (PH) secondary to pulmonary artery thrombi in the context of anti-phospholipid syndrome (APS). Extensive investigations including imaging studies revealed PH. Thromboembolic workup confirmed multiple pulmonary artery thrombi, and anti-phospholipid antibody testing confirmed APS. The patient received anticoagulation therapy tailored to APS management. Follow-up assessments demonstrated significant improvement in PH leading to cessation of syncope episodes...
January 2024: Curēus
https://read.qxmd.com/read/38320591/antiphospholipid-syndrome-pathogenesis-in-2023-an-update-of-new-mechanisms-or-just-a-reconsideration-of-the-old-ones
#8
JOURNAL ARTICLE
Elena Raschi, Maria Orietta Borghi, Francesco Tedesco, Pier Luigi Meroni
Antibodies against phospholipid (aPL)-binding proteins, in particular, beta 2 glycoprotein I (β2GPI), are diagnostic/classification and pathogenic antibodies in antiphospholipid syndrome (APS). β2GPI-aPL recognize their target on endothelium and trigger a pro-thrombotic phenotype which is amplified by circulating monocytes, platelets and neutrophils. Complement activation is required as supported by the lack of aPL-mediated effects in animal models when the complement cascade is blocked. The final result is a localized clot...
February 6, 2024: Rheumatology
https://read.qxmd.com/read/38320585/viewpoint-provoked-thrombosis-in-antiphospholipid-syndrome
#9
JOURNAL ARTICLE
Denis Wahl, Vittorio Pengo
Unprovoked thrombosis (thrombosis occurring without an established environmental factor favouring the episode) is a classic feature of APS. In the general population, provoked venous thromboembolism (VTE) is clearly defined and has clinical and therapeutic differences compared with unprovoked VTE. Whether provoked VTE in the context of APS may lead to a limited treatment duration is not well established. Therefore, careful clinical and laboratory evaluation is needed to identify patients eligible for a limited duration of anticoagulation treatment after provoked VTE...
February 6, 2024: Rheumatology
https://read.qxmd.com/read/38298622/therapeutic-strategy-of-biological-macromolecules-based-natural-bioactive-compounds-of-diabetes-mellitus-and-future-perspectives-a-systematic-review
#10
JOURNAL ARTICLE
Naiyer Shahzad, Abdullah R Alzahrani, Ibrahim Abdel Aziz Ibrahim, Imran Shahid, Ibrahim M Alanazi, Alaa Hisham Falemban, Mohammad Tarique Imam, Nehal Mohsin, Mohd Fahami Nur Azlina, Palanisamy Arulselvan
High blood glucose levels are a hallmark of the metabolic syndrome known as diabetes mellitus. More than 600 million people will have diabetes by 2045 as the global prevalence of the disease continues to rise. Contemporary antidiabetic drugs reduce hyperglycemia and its consequences. However, these drugs come with undesirable side effects, so it's encouraging that research into plant extracts and bioactive substances with antidiabetic characteristics is on the rise. Natural remedies are preferable to conventional anti-diabetic drugs since they are safer for the body, more affordable and have fewer potential adverse effects...
January 30, 2024: Heliyon
https://read.qxmd.com/read/38282799/the-mtor-pathway-in-the-antiphospholipid-syndrome
#11
JOURNAL ARTICLE
Lanlan Ji, Zhuoli Zhang, Andras Perl
This perspective discussed the available evidence on the involvement of mTOR pathway in antiphospholipid syndrome (APS), from the aspects of endothelial cells, platelets, monocytes and anti-phospholipid antibodies (PLs), which may lead to future therapeutic applications of mTOR inhibition in APS.
December 2023: Med Rev (2021)
https://read.qxmd.com/read/38267542/an-immunogenomic-exome-landscape-of-triple-positive-primary-antiphospholipid-patients
#12
JOURNAL ARTICLE
A Guffroy, L Jacquel, Y Seeleuthner, N Paul, V Poindron, F Maurier, V Delannoy, A C Voegeli, P Zhang, B Nespola, A Molitor, M J Apithy, P Soulas-Sprauel, T Martin, R E Voll, S Bahram, V Gies, J L Casanova, A Cobat, B Boisson, R Carapito, A S Korganow
Primary antiphospholipid syndrome is characterized by thrombosis and autoantibodies directed against phospholipids or associated proteins. The genetic etiology of PAPS remains unknown. We enrolled 21 patients with thromboembolic events associated to lupus anticoagulant, anticardiolipin and anti β2 glycoprotein1 autoantibodies. We performed whole exome sequencing. Data were compared to public databases and to a control cohort of 873 non-autoimmune patients. We performed whole exome sequencing and a systematic variant-based analysis in genes associated with thrombosis, in candidate genes previously associated with APS or inborn errors of immunity...
January 24, 2024: Genes and Immunity
https://read.qxmd.com/read/38212567/antiphospholipid-syndrome-are-old-school-vkas-still-the-best-choice
#13
JOURNAL ARTICLE
Marta Chiara Sircana, Giulia Crisci, Federica Giardino, Chiara Pisetta, Nicola Bonadia
No abstract text is available yet for this article.
January 2024: Internal and Emergency Medicine
https://read.qxmd.com/read/38195020/anti-phosphatidyl-serine-prothrombin-aps-pt-antibodies-are-superior-predictors-of-lac-presence-and-aps-diagnoses-a-single-center-study
#14
JOURNAL ARTICLE
Abdulrahman Saadalla, Vijayalakshmi Nandakumar
BACKGROUND AND AIMS: Several non-criteria (NC) anti-phospholipid antibodies (APLA) have been proposed as candidates for antiphospholipid antibody syndrome (APS) diagnosis. The objectives of this study were 1) to determine the association of five different NC-APLA with positivity for Lupus anti-coagulant (LAC) and the criteria antibodies anti-cardiolipin (aCL) and anti-beta glycoprotein (aB2GPI), and 2) to assess the ability of NC-APLA to predict LAC presence and clinical APS diagnoses...
January 7, 2024: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://read.qxmd.com/read/38183501/mboat7-expression-is-associated-with-disease-progression-in-covid-19-patients
#15
JOURNAL ARTICLE
Eman Radwan, Ahmed Abdelaziz, Manal A M Mandour, Abdel-Raheim M A Meki, Maha M El-Kholy, Marwan N Mohamed
BACKGROUND AND AIM: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 caused a pandemic of acute respiratory disease, named coronavirus disease 2019 (COVID-19). COVID-19 became one of the most challenging health emergencies, hence the necessity to find different prognostic factors for disease progression, and severity. Membrane bound O-acyltransferase domain containing 7 (MBOAT7) demonstrates anti-inflammatory effects through acting as a fine-tune regulator of the amount of cellular free arachidonic acid...
January 6, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38145574/how-i-diagnose-and-treat-antiphospholipid-syndrome-in-pregnancy
#16
JOURNAL ARTICLE
D Ware Branch, Ming Y Lim
Antiphospholipid syndrome (APS) is a rare autoimmune disease characterized by arterial, venous, or microvascular thrombosis, pregnancy morbidities, or nonthrombotic manifestations in patients with persistently positive antiphospholipid antibodies. These antibodies bind cellular phospholipids and phospholipid-protein complexes resulting in cellular activation and inflammation that lead to the clinical features of APS. Our evolving understanding of APS has resulted in more specific classification criteria. Patients meeting these criteria should be treated during pregnancy according to current guidelines...
February 29, 2024: Blood
https://read.qxmd.com/read/38070133/prevalence-of-antiphospholipid-syndrome-among-pregnant-women-in-lautech-teaching-hospital-ogbomoso-nigeria
#17
Oloyede Taiwo, Oloyede Taofeek, Ojedokun Samson, Oladibu Olanike, Alatishe Taiwo
BACKGROUND: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by clinical thrombotic events which may be arterial or venous vasculature associated with the presence of antiphospholipid antibodies (aPL) in patient plasma. Majority of the studies done in this part of the world utilized single auto-antibody to phospholipids or phospholipid binding protein which resulted in an underestimation of the actual prevalence of this treatable disease entity. Hence, this study incorporates the use of triple auto-antibodies to determine the prevalence of APS among pregnant women in LAUTECH Teaching Hospital, Ogbomoso...
December 4, 2023: West African Journal of Medicine
https://read.qxmd.com/read/38066904/how-to-diagnose-and-manage-antiphospholipid-syndrome
#18
REVIEW
Anne Hubben, Keith R McCrae
Antiphospholipid antibodies (aPL) are autoimmune antibodies directed toward phospholipids or phospholipid-protein complexes, particularly those containing β2-glycoprotein I (β2GPI). Persistently positive aPL accompanied by arterial or venous thrombosis, or recurrent pregnancy loss, constitutes the antiphospholipid syndrome (APS). Several types of aPL with different specificities have been defined and may be detected in the clinical lab, including lupus anticoagulants (detected using clotting assays) and anticardiolipin, anti-β2GPI and anti-prothrombin/phosphatidylserine antibodies (detected by ELISA); each of the last 3 aPL may be either IgG, IgM, or IgA, though IgA antibodies are not included in criteria for APS...
December 8, 2023: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/38042984/platypnea-orthodeoxia-syndrome-caused-by-patent-foramen-ovale-with-right-to-left-shunt
#19
JOURNAL ARTICLE
Waleed Al Saadi, Ali I Al-Lawati, Mujahid Al Busaidi, Sheeraz Ahmed, Zeyana Alhadhrami, Fahad Alkindi
BACKGROUND Patent Foramen Ovale (PFO) is an important part of fetal circulation. It allows the oxygenated blood from the umbilical cord to bypass the lungs. PFOs usually close after birth due to the sudden change of the hemodynamics associated with the expansion of the lungs however they are known to persist in about 25% of the total population. One of their rare manifestations is Platypnea-Orthodeoxia Syndrome (POS) that presents as dyspnea upon assuming an upright position, which improves upon recumbency, accompanied by hypoxemia...
December 3, 2023: American Journal of Case Reports
https://read.qxmd.com/read/37996701/anomalous-peroxidase-activity-of-cytochrome-c-is-the-primary-pathogenic-target-in-barth-syndrome
#20
JOURNAL ARTICLE
Valerian E Kagan, Yulia Y Tyurina, Karolina Mikulska-Ruminska, Deena Damschroder, Eduardo Vieira Neto, Alessia Lasorsa, Alexander A Kapralov, Vladimir A Tyurin, Andrew A Amoscato, Svetlana N Samovich, Austin B Souryavong, Haider H Dar, Abu Ramim, Zhuqing Liang, Pablo Lazcano, Jiajia Ji, Michael W Schmidtke, Kirill Kiselyov, Aybike Korkmaz, Georgy K Vladimirov, Margarita A Artyukhova, Pushpa Rampratap, Laura K Cole, Ammanamanchi Niyatie, Emma-Kate Baker, Jim Peterson, Grant M Hatch, Jeffrey Atkinson, Jerry Vockley, Bernhard Kühn, Robert Wessells, Patrick C A van der Wel, Ivet Bahar, Hülya Bayir, Miriam L Greenberg
Barth syndrome (BTHS) is a life-threatening genetic disorder with unknown pathogenicity caused by mutations in TAFAZZIN (TAZ) that affect remodeling of mitochondrial cardiolipin (CL). TAZ deficiency leads to accumulation of mono-lyso-CL (MLCL), which forms a peroxidase complex with cytochrome c (cyt c) capable of oxidizing polyunsaturated fatty acid-containing lipids. We hypothesized that accumulation of MLCL facilitates formation of anomalous MLCL-cyt c peroxidase complexes and peroxidation of polyunsaturated fatty acid phospholipids as the primary BTHS pathogenic mechanism...
November 23, 2023: Nature metabolism
keyword
keyword
20610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.